Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The evolution of transdermal/ topical overactive bladder therapy and its benefits over oral therapy.

Literature DB >> 19609406

The evolution of transdermal/ topical overactive bladder therapy and its benefits over oral therapy.

Abstract

Multiple antimuscarinic agents are available for the treatment of overactive bladder. Many of the agents have undergone reformulation in an attempt to improve patient adherence and drug tolerability. Oxybutynin evolved from an immediate-release pill to a once-daily oral preparation, and is now available as a transdermal patch and gel. This article discusses the clinical impact of oxybutynin reformulation and reviews the evolution and benefits of transdermal therapy.

Entities: Chemical Disease Species

Keywords: Oxybutynin; Reformulation; Transdermal therapy

Year: 2009 PMID： 19609406 PMCID： PMC2709332

Source DB: PubMed Journal: Rev Obstet Gynecol ISSN： 1941-2797

25 in total

Review 1. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Authors: Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein
Journal: Urology Date: 2003-01 Impact factor: 2.649

Review 2. Transdermal delivery of drugs for urologic applications: basic principles and applications.

Authors: Victor W Nitti; Steven Sanders; David R Staskin; Roger R Dmochowski; Peter K Sand; Scott MacDiarmid; Howard I Maibach
Journal: Urology Date: 2006-04 Impact factor: 2.649

Review 3. Medical treatment and medical side effects in urinary incontinence in the elderly.

Authors: J W Thüroff; E Chartier-Kastler; J Corcus; J Humke; U Jonas; H Palmtag; E A Tanagho
Journal: World J Urol Date: 1998 Impact factor: 4.226

4. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland.

Authors: K Waldeck; B Larsson; K E Andersson
Journal: J Urol Date: 1997-03 Impact factor: 7.450

Review 5. Transdermal drug delivery and cutaneous metabolism.

Authors: R H Guy; J Hadgraft; D A Bucks
Journal: Xenobiotica Date: 1987-03 Impact factor: 1.908

Review 6. Compliance with treatment regimens in chronic asymptomatic diseases.

Authors: N H Miller
Journal: Am J Med Date: 1997-02-17 Impact factor: 4.965

7. Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion.

Authors: Tomomi Oki; Ayako Toma-Okura; Shizuo Yamada
Journal: J Pharmacol Exp Ther Date: 2005-11-10 Impact factor: 4.030

8. Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group.

Authors: D M Gleason; J Susset; C White; D R Munoz; P K Sand
Journal: Urology Date: 1999-09 Impact factor: 2.649